Is Ionis Pharmaceuticals (IONS) Undervalued After TRYNGOLZA EU Approval And Diranersen Data?
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
Ionis Pharmaceuticals (IONS) is under scrutiny after receiving European approval for TRYNGOLZA and presenting Phase 2 data for diranersen, yet its share price has fallen significantly. Analysts view the company as 61% undervalued, with a fair value of $69.30, based on the potential of its APOC3 and neurology franchises.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.